Chemotherapy-Induced-Peripheral-Neuropathy-Pipeline-Review-H2-2017

Chemotherapy-Induced-Peripheral-Neuropathy-Pipeline-Review-H2-2017


  • Products Id :- GMDHC9671IDB
  • |
  • Pages: 136
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chemotherapy Induced Peripheral Neuropathy-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy-Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape.

Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 3, 1, 23, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy (Toxicology).

The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chemotherapy Induced Peripheral Neuropathy (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy (Toxicology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chemotherapy Induced Peripheral Neuropathy-Overview

Chemotherapy Induced Peripheral Neuropathy-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chemotherapy Induced Peripheral Neuropathy-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chemotherapy Induced Peripheral Neuropathy-Companies Involved in Therapeutics Development

Achelios Therapeutics Inc

Advinus Therapeutics Ltd

Apollo Endosurgery Inc

Aptinyx Inc

Asahi Kasei Pharma Corp

Can-Fite BioPharma Ltd

Celgene Corp

Eisai Co Ltd

Immune Pharmaceuticals Inc

Insys Therapeutics Inc

Kineta Inc

KPI Therapeutics Inc

Krenitsky Pharmaceuticals Inc

Midatech Pharma US Inc

Mundipharma International Ltd

Nemus Bioscience Inc

Neurocentrx Pharma Ltd

Panacea Pharmaceuticals Inc

PeriphaGen Inc

PledPharma AB

Sova Pharmaceuticals Inc

Trevena Inc

WEX Pharmaceuticals Inc

Chemotherapy Induced Peripheral Neuropathy-Drug Profiles

(amitriptyline + ketamine hydrochloride)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACY-1083-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-1710-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-2009-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APX-3330-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BR-297-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimiracetam-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Chemotherapy Induced Peripheral Neuropathy and Neurology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Peripheral Neuropathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DX-0332-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-2072-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KCP-400-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoprofen-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-544-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KRN-5500-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LM-11A31BHS-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lpathomab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MR-309-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2111-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-2222-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NRX-2922-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NT-24336-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAN-811-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGN-503-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piclidenoson-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pirenzepine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PP-095-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Q-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ricolinostat-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Chemotherapy Induced Peripheral Neuropathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Pain-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block Nav 1.8 for Chemotherapy Induced Peripheral Neuropathy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target S1PR for Central Nervous System and Toxicology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tetrodotoxin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

thrombomodulin alfa-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XT-150-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZF-198-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chemotherapy Induced Peripheral Neuropathy-Dormant Projects

Chemotherapy Induced Peripheral Neuropathy-Discontinued Products

Chemotherapy Induced Peripheral Neuropathy-Product Development Milestones

Featured News & Press Releases

Aug 02, 2017: Nemus Bioscience Announces Presentation of NB2111 Analgesic and Anti-Addiction Data at NIH-Sponsored Cannabinoid Conference

Jul 13, 2017: Apexian Pharmaceuticals Announces FDA Agreement For Inclusion of Chemotherapy Induced Peripheral Neuropathy (CIPN) Indication Under Currently Approved IND

Jun 29, 2017: PledPharma strengthens the management team with a Vice President Product Strategy and Development

Mar 08, 2017: Regenacy Pharmaceuticals Demonstrates Reversal of Chemotherapy-Induced Peripheral Neuropathy with HDAC6 Inhibitor Ricolinostat in Preclinical Model

Dec 01, 2016: Nemus Bioscience Announces Milestones In The Development Of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient For Drug Candidate NB2111 And Formulation Contract With AMRI And Catalent Pharma Solutions

Jun 02, 2016: NEMUS Bioscience Identifies Unique Cannabidiol Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program

May 19, 2016: PledPharma to present the Phase IIb PLIANT study data at ASCO 2016

May 17, 2015: Wex Pharmaceuticals Announces Presentation Of Preclinical Data On Chemotherapy-Induced Peripheral Neuropathy And Burn Injury Pain At The 2015 American Pain Society Conference On Its Lead Compound, Halneuron (TTX)

Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA

Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program

Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA

Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation

Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Achelios Therapeutics Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Advinus Therapeutics Ltd, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Apollo Endosurgery Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Aptinyx Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Asahi Kasei Pharma Corp, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Can-Fite BioPharma Ltd, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Celgene Corp, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Eisai Co Ltd, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Immune Pharmaceuticals Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Insys Therapeutics Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Kineta Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by KPI Therapeutics Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Krenitsky Pharmaceuticals Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Midatech Pharma US Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Mundipharma International Ltd, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Nemus Bioscience Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Neurocentrx Pharma Ltd, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Panacea Pharmaceuticals Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by PeriphaGen Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by PledPharma AB, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Sova Pharmaceuticals Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by Trevena Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Pipeline by WEX Pharmaceuticals Inc, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Dormant Projects, H2 2017

Chemotherapy Induced Peripheral Neuropathy-Dormant Projects, H2 2017 (Contd..1), H2 2017

Chemotherapy Induced Peripheral Neuropathy-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Achelios Therapeutics Inc

Advinus Therapeutics Ltd

Apollo Endosurgery Inc

Aptinyx Inc

Asahi Kasei Pharma Corp

Can-Fite BioPharma Ltd

Celgene Corp

Eisai Co Ltd

Immune Pharmaceuticals Inc

Insys Therapeutics Inc

Kineta Inc

KPI Therapeutics Inc

Krenitsky Pharmaceuticals Inc

Midatech Pharma US Inc

Mundipharma International Ltd

Nemus Bioscience Inc

Neurocentrx Pharma Ltd

Panacea Pharmaceuticals Inc

PeriphaGen Inc

PledPharma AB

Sova Pharmaceuticals Inc

Trevena Inc

WEX Pharmaceuticals Inc

Chemotherapy Induced Peripheral Neuropathy Therapeutic Products under Development, Key Players in Chemotherapy Induced Peripheral Neuropathy Therapeutics, Chemotherapy Induced Peripheral Neuropathy Pipeline Overview, Chemotherapy Induced Peripheral Neuropathy Pipeline, Chemotherapy Induced Peripheral Neuropathy Pipeline Assessment

select a license
Single User License
USD 2000 INR 142600
Site License
USD 4000 INR 285200
Corporate User License
USD 6000 INR 427800

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com